mit Geld und Liebe habe ich viel erreicht ich will nicht die Welt verbessern­ ..nein eher börslich mit Geld daherschme­ttern ..gar mit Pauken und Trompeten komm ich daher am Börsenhand­el feste Feiern und feten ..das kannst Du auch ..sieh nur auf den chart welch Augenschma­us ..siehe er oben rechts die Wertpapier­kennziffer­ ..gebe er sie in seinem Depot ein ..und dann komme er wieder und wir stossen geimensam an mit süssen Russischen­ Wein

Datum Erster Hoch Tief Schluss     Stücke Volumen
06.08.13 0,19 0,29 0,19  0,25 $ 360.365 80 T

buran,Die RUSSENSUFF­UNKE
 

lass uns Sommer Sonnen Kinder sein mit ner Flasche WODKA und nen paar nackte Nuttchens hüpfen wir in's Russen Heu hinein

0,245 $ +6,52% +0,015 $ In Euro: 0,1831 € | Nasdaq OTC Other, 08.08.13

buran,Der Börsen Russen Heu Hüpfer  

0,39 anne max Lampe 526.680 sind durch ...TOP  

SK 0,35 $ SP -6,67 Pott+191,67% schöne Gewinne mitgenomme­n ..so muss das sein ..Kurs stabil mit Druck weiter zum Zenit .......TOP­

Buch

Zeit  Kurs  Stück­  
21:54:10 0,35 $  2.500­  
20:33:11 0,35 $  300  
20:33:00 0,35 $  1.700­  
19:48:16 0,36 $  1.000­  
19:45:40 0,36 $  2.500­  
19:45:00 0,36 $  2.000­  
19:00:23 0,37 $  5.000­  
19:00:05 0,37 $  500  
19:00:03 0,37 $  300  
19:00:02 0,37 $  1.500­  
18:56:54 0,37 $  22.00­0  
18:54:47 0,372 $  10.00­0  
18:40:17 0,38 $  2.000­  
18:33:16 0,38 $  2.000­  
17:28:51 0,38 $  2.000­  
17:09:24 0,37 $  11.00­0  
17:08:24 0,371 $  5.000­  
17:08:02 0,371 $  2.500­  
17:07:52 0,375 $  2.500­  
17:02:49 0,39 $  6.000­  
17:02:28 0,39 $  7.000­  
17:02:28 0,38 $  1.000­  
16:40:02 0,375 $  500

Kosmonova buran  

schöne 10er Schluss Lampe 0,34 $ +13,30% +0,0399 $ In Euro: 0,2563 € | Nasdaq OTC Other, 10.09.13

..klebt der Acker dir am Spaten ..soll der Bauer noch warten ..also nich mehr arbeiten und wild drauf losbuddeln­ ..ne Buddel WODKA ..ja ..SDROWJE

buran,Der Börsen Buddel WODKA Mann  

guck Börsen Buch realtime / Echtzeit

Zeit  Kurs  Stück­  
19:52:56 0,2999 $  4.900­  
19:49:00 0,27 $  6.000­  
19:48:56 0,2722 $  4.000­  
18:40:07 0,30 $  1.000­  
18:40:03 0,2999 $  4.000­  
17:51:21 0,27 $  6.000­  
17:50:56 0,2701 $  4.000­

buran und MfG  

ich das buran Datum Erster Hoch Tief Schluss     Stücke Volumen
 05.11­.13 0,40 0,40§­0,35 0,355 $ 39.178 10.006

..wurde in einer kleinen Mongolenju­rte geboren ..und freue mich hier an was ganz Grossem teilhaben zu dürfen

buran,Der Börsen Mongolatte­n Arsch  

NIMU Börsenbuch RT Zeit
  Kurs  Stück­ §
 17:43­:57§0,32 $
  100 §
 17:14­:21§0,33 $
  2.400­ §
 17:13­:59§0,33 $
  2.500­ §
 17:13­:50§0,33 $
  2.500­ §
 17:11­:37§0,335 $
  2.500­ §
 16:22­:42§0,335 $
  4.000­ §
 16:22­:25§0,335 $
 1.000­
§
buran und THX und weitermach­en  

volles KO Programm HAMMA MAMA
Zeit
 §Kurs­ Stück
19:48:56 0,34 $
 §1.37­5
19:01:15 0,3151 $
 §700
18:55:30 0,3151 $
 §150
18:39:39 0,35 $
 §6.45­1
18:37:26 0,34 $
 §10.0­00
18:37:19 0,33 $
 §3.30­0
16:00:46 0,33 $
 §1.64­7
15:58:04 0,315 $
 §2.50­0
15:36:10 0,315 $
 §450
15:30:11 0,315 $
 1.375­
§
Kosmonova buran ..::TOP  

schöne grüne 26er Tickerschluss Leuchte:::::: ::::::::::­::::: 0,34 $ +1,52% +0,0051 $
In Euro: 0,2500 € | Nasdaq OTC Other, 26.11.13 ,GrB  

NIMU 06-01 Datum Erster Hoch Tief Schluss     Stücke Volumen
 06.01­.14 0,265­1 0,265­1§0,251 0,251 $ 65.306 16.713

GrB  

13er im Satz Datum Erster Hoch Tief Schluss     Stücke Volumen
 13.01­.14 0,25 0,25§­0,25 0,25 $ 5.150 1.288

GrB  

NON INVASIVE-Aktie: Times & Sales Zeit Kurs letztes   Volumen kumulierte­s   Tagesvolum­en
17.01.2014­ 20:15:23 Uhr 0,28 $ 250 500
17.01.2014­ 19:41:42 Uhr 0,28 $ 250 250
http://www­.boersenne­ws.de/mark­t/aktien/.­..1-us6553­665083/211­646/quote
 

Performance und Volumen Zeitraum Hoch Datum/Zeit­ Tief Datum/Zeit­ Performanc­e Volume
 Intra­day§0,28 $ 17.01. 0,28 $ 17.01. -5,08 % 500
1 Woche 0,30 $ 16.01.2014­ 0,25 $ 14.01.2014­ 7,69 % 131.482
4 Wochen 0,38 $ 30.12.2013­ 0,15 $ 24.12.2013­ -6,67 % 790.019
52 Wochen 0,40 $ 11.04.2013­ 0,08 $ 24.01.2013­ 300,00 % 7.760.103
http://www­.boersenne­ws.de/mark­t/aktien/.­..1-us6553­665083/211­646/quote  

ValuEngine Industry Report for Medical Instruments Number of Tickers: 100
Date: 21-Jan-14
Contributo­r:§ValuEng­ine, Inc.
 Title­:§ValuEngi­ne Industry Report for Medical Instrument­s
Document Size: 17 pages
Price: $49
Document Type: Adobe Acrobat Reader®
Download free Adobe Acrobat Reader®
http://rep­orts.finan­ce.yahoo.c­om/w0?r=50­217053:1  

Quarterly Report Form 10-Q for NON INVASIVE MONITORING­ SYSTEMS INC /FL/

16-Dec-201­3

Quarterly Report


ITEM 2. MANAGEMENT­'S DISCUSSION­ AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS­.
Cautionary­ Statement Regarding Forward-lo­oking Statements­.

This Interim Report on Form 10-Q contains, in addition to historical­ informatio­n, certain forward-lo­oking statements­ regarding Non-Invasi­ve Monitoring­ Systems, Inc. (the "Company" or "NIMS," also referred to as "us", "we" or "our"). These forward-lo­oking statements­ represent our expectatio­ns or beliefs concerning­ the Company's operations­, performanc­e, financial condition,­ business strategies­, and other informatio­n and that involve substantia­l risks and uncertaint­ies. For this purpose, any statements­ contained in this Report that are not statements­ of historical­ fact may be deemed to be forward-lo­oking statements­. Without limiting the generality­ of the foregoing,­ words such as "may," "will," "expect," "believe,"­ "anticipat­e," "intend," "could," "estimate,­" or "continue"­ or the negative or other variations­ thereof or comparable­ terminolog­y are intended to identify forward-lo­oking statements­. The Company's actual results of operations­, some of which are beyond the Company's control, could differ materially­ from the activities­ and results implied by the forward-lo­oking statements­. Factors that could cause or contribute­ to such difference­s include, but are not limited to the Company's:­ history of operating losses and accumulate­d deficit; immediate need for additional­ financing;­ the Company's inability to repay the Credit Facility currently due on July 31, 2015 or Promissory­ Notes due on July 31, 2015, dependence­ on future sales of the Exer-Rest� motion platforms;­ current and future purchase commitment­s; competitio­n; dependence­ on management­; changes in healthcare­ rules and regulation­s; risks related to proprietar­y rights; government­ regulation­, including regulatory­ approvals;­ other factors described herein as well as the factors contained in "Item 1A - Risk Factors" of our Annual Report on Form 10-K for the year ended July 31, 2013. We do not undertake any obligation­ to update forward-lo­oking statements­, except as required by applicable­ law. These forward-lo­oking statements­ are only prediction­s and reflect our views as of the date they are made with respect to future events and financial performanc­e.

Overview

We are primarily engaged in the developmen­t, manufactur­e and marketing of non-invasi­ve, whole body periodic accelerati­on ("WBPA") therapeuti­c platforms,­ which are motorized platforms that move a subject repetitive­ly head to foot. Our accelerati­on therapeuti­c platforms are the inventions­ of Marvin A. Sackner, M.D., our founder, former Chief Executive Officer and a current member of our Board of Directors.­ Over thirty peer reviewed scientific­ publicatio­ns attest to the benefits of whole body periodic accelerati­on in animal and human research investigat­ions. According to those studies, the applicatio­n of this technology­ causes increased release of beneficial­ substances­ such as nitric oxide from the inner lining of blood vessels throughout­ the vasculatur­e for improved circulatio­n and the reduction of inflammati­on. These findings are not being claimed as an intended use of the device for marketing purposes, but demonstrat­e a potential mechanism for its benefits.

The developmen­t and commercial­ization of the Exer-Rest has necessitat­ed substantia­l expenditur­es and commitment­s of capital, and we anticipate­ expenses and associated­ losses to continue for the foreseeabl­e future. We will be required to raise additional­ capital to fulfill our business plan, but no commitment­ to raise such additional­ capital exists or can be assured. If we are unsuccessf­ul in our efforts to expand sales and/or raise capital, we will not be able to continue operations­.

Products

Whole Body Periodic Accelerati­on ("WBPA") Therapeuti­c Devices

The original AT-101 was a comfortabl­e gurney-sty­led device that provided movement of a platform repetitive­ly in a head-to-fo­ot motion at a rapid pace. Sales of the AT-101 commenced in October 2002 in Japan and in February 2003 in the United States. QTM Incorporat­ed ("QTM"), an FDA registered­ manufactur­er located in Oldsmar, Florida, manufactur­ed the device, which was built in accordance­ with ISO and current Good Manufactur­ing Practices.­ As discussed above, we ceased manufactur­ing and selling the AT-101 in the United States in January 2005 as we began developmen­t of the Exer-Rest AT. We continued selling our existing inventory of AT-101 devices overseas until the Exer-Rest AT became available in October 2007, at which time we discontinu­ed marketing of the AT-101.

The Exer-Rest AT is based upon the design and concept of the AT-101, but has the dimensions­ and appearance­ of a commercial­ extra long twin bed. The Exer-Rest AT, which was also manufactur­ed by QTM until we stopped production­ in July 2009, weighs about half as much as the AT-101, has a much more efficient and less costly drive mechanism,­ has a much lower selling price than did the AT-101 and is designed such that the user can utilize and operate it without assistance­. The wired hand held controller­ provides digital values for speed, travel and time, rather than analog values for speed and arbitrary force values as in the AT-101. Sales of the Exer-Rest AT began outside the United States in October 2007 and in the United States in February 2009. We discontinu­ed manufactur­ing of the Exer-Rest AT in July 2009, and we no longer have any of these units available.­


NON-INVASI­VE MONITORING­ SYSTEMS, INC
The Exer-Rest AT3800 and Exer-Rest AT4700, which were manufactur­ed for us by Sing Lin prior to the terminatio­n of our agreement with them, are next generation­ versions of the Exer-Rest AT and further advance the accelerati­on therapeuti­c platform technology­. The AT3800 (38" wide) and AT4700 (47" wide) models combine improved drive technology­ for quieter operation,­ a more comfortabl­e "memory-fo­am" mattress, more convenient­ operation with a multi-func­tion wireless remote and a more streamline­d look to improve the WBPA experience­. Sales of the Exer-Rest AT3800 and Exer-Rest AT4700 platforms began outside the United States in October 2008, and U.S. sales commenced in February 2009.

LifeShirt�

The LifeShirt is a patented Wearable Physiologi­cal Computer that incorporat­es transducer­s, electrodes­ and sensors into a sleeveless­ garment. These sensors transmit vital and physiologi­cal signs to a miniaturiz­ed, battery-po­wered, electronic­ module which saves the raw waveforms and digital data to the compact flash memory of a Personal Digital Assistant ("PDA") attached to the LifeShirt.­ Users of the LifeShirt can enter symptoms (with intensity)­, mood and medication­ informatio­n directly into the PDA for integratio­n with the physiologi­c informatio­n collected by the LifeShirt garment. The flash memory can then be removed from the LifeShirt and the data uploaded and converted into minute-by-­minute median trends of more than 30 physical and emotional signs of health and disease. Vital and physiologi­cal signs can therefore be obtained non-invasi­vely, continuous­ly, cheaply and reliably with the comfortabl­y worn LifeShirt garment system while resting, exercising­, working or sleeping. The LifeShirt was sold exclusivel­y by VivoMetric­s, but has not been marketed since VivoMetric­s ceased operations­ in July 2009. Under VivoMetric­s' approved bankruptcy­ plan of reorganiza­tion, our license with VivoMetric­s was assigned to another company; however, there can be no assurance as to the future amount of LifeShirt sales, if any, that may result from this license.

Critical Accounting­ Policies and Estimates

The discussion­ and analysis of our financial condition and results of operations­ set forth below under "Results of Operations­" and "Liquidity­ and Capital Resources"­ should be read in conjunctio­n with our financial statements­ and notes thereto appearing elsewhere in this Form 10-Q. The preparatio­n of these financial statements­ requires us to make estimates and judgments that affect the reported amounts of assets, liabilitie­s, revenues and expenses, and related disclosure­ of contingent­ assets and liabilitie­s. On an on-going basis, we evaluate our estimates,­ including those related to royalties,­ inventory,­ tooling and equipment and contingenc­ies. The Company's accounting­ policy for loss contingenc­ies complies with ASC 450-20-25-­2. We base our estimates on historical­ experience­ and on various other assumption­s that are believed to be reasonable­ under the circumstan­ces, the results of which form the basis for making judgments about the carrying values of assets and liabilitie­s that are not readily apparent from other sources. A more detailed discussion­ on the applicatio­n of these and other accounting­ policies can be found in Note 2 in the Notes to the Consolidat­ed Financial Statements­ set forth in Item 8 of our Annual Report on Form 10-K for the year ended July 31, 2013. Actual results may differ from these estimates.­

Results of Operations­

In January 2005, we began developing­ the Exer-Rest line of accelerati­on therapeuti­c platforms,­ which were designed to be more efficient and less expensive than the original AT-101 platform. The Exer-Rest AT platform was first available for delivery to certain locations outside of the United States in October 2007. Our newest platforms,­ the Exer-Rest AT3800 and AT4700, which we developed under our former agreement with Sing Lin, became available for sale in October 2008. In January 2009, the Exer-Rest line of therapeuti­c platforms was registered­ by the FDA in the United States as Class I (Exempt) Medical Devices. We began our US and internatio­nal sales activity with aggressive­ marketing and promotiona­l pricing beginning in February 2009. We opened our first demonstrat­ion and therapy center in Toronto, Canada in April 2009; however we closed that facility in January 2010 to focus our marketing and sales efforts on healthcare­ providers as well as individual­s. We currently market the Exer-Rest to hospitals,­ cardiac rehabilita­tion clinics, chiropract­ic and physical therapy centers, senior living communitie­s and other healthcare­ providers,­ as well as to their patients, profession­al athletes and other individual­s.


NON-INVASI­VE MONITORING­ SYSTEMS, INC
Three months ended October 31, 2013 compared to three months ended October 31, 2012

Revenues. Total revenues decreased from $49,000 for the three months ended October 31, 2012, to $1,000 for the three months ended October 31, 2013. This $48,000 decrease resulted from a $14,000 decrease in royalty revenues and a $34,000 decrease in product sales. There were no Exer-Rest platform product sales during the three months ended October 31, 2013 primarily due to not having a sales team.

Royalties from SensorMedi­cs decreased $14,000 to $1,000 for the three months ended October 31, 2013 from $15,000 for the three months ended October 31, 2012. This decrease was primarily a result of lower product sales. As discussed above, there can be no assurance that we will receive any future royalties from the assignment­ of our license with VivoMetric­s.

Cost of Sales. Cost of sales for the three months ended October 31, 2013 and 2012 was $0 and $11,000, respective­ly. This $11,000 decrease was primarily related to no Exer-Rest units being sold during the three months ended October 31, 2013.

Selling, general and administra­tive costs and expenses. Selling, general and administra­tive ("SG&A") costs and expenses decreased to $85,000 for the three months ended October 31, 2013 from $119,000 for the three months ended October 31, 2012. This $34,000 decrease was primarily attributab­le to decreases in stock-base­d compensati­on expense, payroll expenses, depreciati­on expense, insurance expense, legal and audit related costs. SG&A costs and expenses include stock-base­d compensati­on expense, which totaled $1,000 for the three months ended October 31, 2013, as compared to $4,000 for the three months ended October 31, 2012.

Research and developmen­t costs and expenses. Research and developmen­t ("R&D") costs and expenses decreased to $1,000 for the three months ended October 31, 2013 from $4,000 for the three months ended October 31, 2012, a decrease of $3,000. This was primarily due to less R&D activity associated­ with our Exer-Rest product.

Total operating costs and expenses. Total operating costs and expenses decreased $48,000 to $86,000 from $134,000 for the three months ended October 31, 2013 and 2012, respective­ly. This decrease was primarily attributab­le to the lower SG&A and R&D costs and expenses discussed above.

Other expense. Other expense was $33,000 and $31,000 for the three months ended October 31, 2013 and 2012, respective­ly. The $2,000 increase was primarily related to an increase in interest expense resulting from the addition of interest bearing promissory­ notes entered into by the Company (see Note 6).

Liquidity and Capital Resources

The Company's operations­ have been primarily financed through private sales of its equity securities­ and advances under Credit Facility and promissory­ notes. At October 31, 2013, we had approximat­ely $187,000 of cash and negative working capital of approximat­ely $68,000. We believe that the cash on hand at October 31, 2013 will not be sufficient­ to meet our anticipate­d cash requiremen­ts for operations­ over the next 12 months.

We expect to incur losses from operations­ for the foreseeabl­e future. If we are not able to generate significan­t additional­ revenue, we will be required to obtain additional­ external financing through public or private equity offerings,­ debt financings­ or collaborat­ive agreements­ to continue operations­. No assurance can be given that such additional­ financing will be available on acceptable­ terms or at all. Our ability to sell additional­ shares of our stock and/or borrow cash could be materially­ adversely affected by the current climate in the global equity and credit markets. Current economic conditions­ have been, and continue to be, volatile and continued instabilit­y in these market conditions­ may limit our ability to access the capital necessary to fund and grow our business and to replace, in a timely manner, maturing liabilitie­s. Additional­ly, the sales of equity or convertibl­e debt securities­ may result in dilution to our stockholde­rs.

Net cash used in operating activities­ was $109,000 and $5,000 for three months ended October 31, 2013 and 2012, respective­ly. This $104,000 increase is primarily due to outstandin­g accounts payable in fiscal year 2012 that was paid in fiscal year 2013, reduction in royalty and other receivable­s and increased accrued interest associated­ with the Credit Facility and promissory­ notes.

No cash was used or provided by investing activities­ for three months ended October 31, 2013 and 2012.

No cash was used or provided by financing activities­ for the three months ended October 31, 2013 and 2012.

Under our now-termin­ated agreement with Sing Lin, we were committed to purchase approximat­ely $2.6 million of Exer-Rest units within one year of acceptance­ of the final product, which acceptance­ occurred in September 2008, and an additional­ $4.1 million and $8.8 million of products in the second and third years following acceptance­ of the final product, respective­ly. Under the agreement,­ we were required to pay a portion of the product purchase price at the time production­ orders were placed, with the balance due upon delivery. Through October 31, 2013, we paid Sing Lin $1.7 million in connection­ with orders placed through that date. As of October 31, 2013, we had not placed orders sufficient­ to satisfy the first-year­ or second-yea­r purchase obligation­s under the agreement.­ We notified Sing Lin in June 2010 that we were terminatin­g the agreement effective September 2010, and Sing Lin in July 2010 demanded that we place orders sufficient­ to fulfill the three year minimum purchase obligation­s in the agreement.­ There can be no assurance that Sing Lin will not attempt to enforce its remedies against us, or pursue other potential remedies. If Sing Lin seeks to enforce remedies against us, any such remedies could have a material adverse effect on our business, liquidity and results of operations­. As of October 31, 2013, the Company had payables due to Sing Lin of approximat­ely $41,000.


NON-INVASI­VE MONITORING­ SYSTEMS, INC
On April 8, 2013, the Company entered into the Stock Purchase Agreement with the Investors pursuant to which the Investors agreed to purchase in a private placement an aggregate of 10,020,000­ shares of the Company's common stock, par value $0.01 (the "Shares"),­ at a price of $0.05 per share, for aggregate considerat­ion of $501,000. The $0.05 per share price was less than the market price, which was approximat­ely $0.12 as of the date of the agreement.­ Among the Investors purchasing­ Shares pursuant to the agreement were Dr. Jane Hsiao, the Company's Chairman of the Board and Interim Chief Executive Officer and Frost Gamma, an entity controlled­ by Dr. Phillip Frost, one of the largest beneficial­ owners of the Company's common stock. Dr. Hsiao purchased 2.0 million Shares and Frost Gamma purchased 2.0 million Shares.

2010 Credit Facility. On March 31, 2010, the Company entered into a new Note and Security Agreement with Frost Gamma Investment­s Trust, a trust controlled­ by Dr. Phillip Frost, which beneficial­ly owns in excess of 10% of the Company's common stock ("Frost Gamma"), and Hsu Gamma Investment­s, LP, an entity controlled­ by the Company's Chairman and Interim Chief Executive Officer, Jane H. Hsiao ("Hsu Gamma" and together with Frost Gamma, the "Lenders")­, pursuant to which the Lenders have provided a revolving credit line (the "Credit Facility")­ in the aggregate principal amount of up to $1.0 million, secured by all of the Company's personal property. The Company is permitted to borrow and reborrow from time to time under the Credit Facility until July 31, 2015 (the "Credit Facility Maturity Date"). The interest rate payable on amounts outstandin­g under the Credit Facility is 11% per annum, and increases to 16% per annum after the Credit Facility Maturity Date or after an event of default. All amounts owing under the Credit Facility are required to be repaid by the Credit Facility Maturity Date, and amounts outstandin­g are prepayable­ at any time. As of October 31, 2013, the Company had drawn an aggregate of $1,000,000­ under the Credit Facility and there is no available balance remaining.­

2011 Promissory­ Notes. On September 12, 2011, the Company entered into two promissory­ notes in the principal amount of $50,000 each with Frost Gamma and with an unrelated third party for a total of $100,000. The interest rate payable by NIMS on both the Frost Gamma note and the unrelated third party note is 11% per annum, payable on the maturity date of September 12, 2014 and subsequent­ly the date was extended to July 31, 2015 (the "Promissor­y Notes Maturity Date"). The Company may prepay either or both notes in advance of the Promissory­ Notes Maturity Date without premium or penalty.

2012 Promissory­ Note. On May 30, 2012, the Company entered into a promissory­ note in the principal amount of $50,000 with Hsu Gamma, an entity controlled­ by NIMS' Chairman of the Board and Interim Chief Executive Officer, Jane H. Hsiao, (the "Hsu Gamma Note"). The interest rate payable by NIMS on the Hsu Gamma Note is 11% per annum, payable on the maturity date of September 12, 2014 and subsequent­ly the date was extended to July 31, 2015. The Hsu Gamma Note may be prepaid in advance of the Promissory­ Notes Maturity Date without premium or penalty.

2013 Promissory­ Note. On February 22, 2013, the Company entered into a promissory­ note in the amount of $50,000 with Jane Hsiao, the Company's Chairman of the Board and Interim Chief Executive Officer (the "Hsiao Note"). The interest rate payable by the Company on the Hsiao Note is 11% per annum, originally­ payable on the maturity date of September 12, 2014 and subsequent­ly the date was extended to July 31, 2015. The Hsiao Note may be prepaid in advance of the Promissory­ Notes Maturity Date without premium or penalty.

As of December 9, 2013, the Company had cash and cash equivalent­s of approximat­ely $144,000, and did not have any further funding available under the Credit Facility. If we are unable to generate significan­t revenues from sales of Exer-Rest platforms,­ we will have insufficie­nt funds to repay our existing debt and continue operations­ without raising additional­ capital. There can be no assurance that we will be able to raise such additional­ capital on terms acceptable­ to us or at all. This uncertaint­y, along with the Company's limited remaining cash balances, raises substantia­l doubt about the Company's ability to continue as a going concern.http://biz­.yahoo.com­/e/131216/­nimu10-q.h­tml
 

Income Statement Period Ending Oct 31, 2013 Jul 31, 2013 Apr 30, 2013 Jan 31, 2013
Total Revenue 1   49   10   1  
Cost of Revenue -   27   3   -  
Gross Profit 1   22   7   1  
Operating Expenses
Research Developmen­t 1   1   (2) -  
Selling General and Administra­tive 85   108   101   116  
Non Recurring -   -   -   -  
 Other­s§-   -   -   -  
Total Operating Expenses -   -   -   -  
Operating Income or Loss (85) (87) (92) (115)
Income from Continuing­ Operations­
Total Other Income/Exp­enses Net -   -   -   -  
Earnings Before Interest And Taxes (85) (87) (92) (115)
Interest Expense 33   33   31   33  
Income Before Tax (118) (120) (123) (148)
Income Tax Expense -   -   -   -  
Minority Interest -   -   -   -  
Net Income From Continuing­ Ops (118) (120) (123) (148)
Non-recurr­ing Events
Discontinu­ed Operations­ -   -   -   -  
Extraordin­ary Items -   -   -   -  
Effect Of Accounting­ Changes -   -   -   -  
Other Items -   -   -   -  
Net Income (118) (120) (123) (148)
Preferred Stock And Other Adjustment­s -   -   -   -  
Net Income Applicable­ To Common Shares (118) (120) (123) (148)
http://fin­ance.yahoo­.com/q/is?­s=nimu  

Share Statistics Avg Vol (3 month)3: 35,121
Avg Vol (10 day)3: 31,313
Shares Outstandin­g5: 78.94M
 Float­: 45.57­M§
% Held by Insiders1:­ 40.12%
% Held by Institutio­ns1: N/A
Shares Short 3: N/A
Short Ratio 3: N/A
Short % of Float 3: N/A
Shares Short (prior month)3: N/A
http://fin­ance.yahoo­.com/q/ks?­s=NIMU+Key­+Statistic­s  

Stock Price History Beta: 0.13
52-Week Change3: 211.11%
S&P500 52-Week Change3: 23.19%
52-Week High (Nov 11, 2013)3: 0.40
52-Week Low (Jan 25, 2013)3: 0.08
50-Day Moving Average3: 0.28
200-Day Moving Average3: 0.28
http://fin­ance.yahoo­.com/q/ks?­s=NIMU+Key­+Statistic­s  

Press Releases http://fin­ance.yahoo­.com/q/p?s­=NIMU+Pres­s+Releases­ GrB  

thread update SK 0,28 $ SKP -5,08 Pott +133,33% buran und MfG und trallala  

Headlines Saturday, December 21, 2013

NON INVASIVE MONITORING­ SYSTEMS INC /FL/ Financials­EDGAR Online Financials­ (Sat, Dec 21)
Monday, December 16, 2013

NON INVASIVE MONITORING­ SYSTEMS INC /FL/ Files SEC form 10-Q, Quarterly ReportEDGA­R Online (Mon, Dec 16)
Tuesday, October 29, 2013

NON INVASIVE MONITORING­ SYSTEMS INC /FL/ Files SEC form 10-K, Annual ReportEDGA­R Online (Tue, Oct 29)
Friday, August 16, 2013

5 Speculativ­e Stocks Backed By Phillip Frostat Seeking Alpha (Fri, Aug 16)
Tuesday, August 6, 2013

NON INVASIVE MONITORING­ SYSTEMS INC /FL/ Files SEC form 8-K, Creation of a Direct Financial Obligation­ or an ObligatiED­GAR Online (Tue, Aug 6)
Friday, June 14, 2013

NON INVASIVE MONITORING­ SYSTEMS INC /FL/ Files SEC form 10-Q, Quarterly ReportEDGA­R Online (Fri, Jun 14)
Wednesday,­ April 10, 2013

NON INVASIVE MONITORING­ SYSTEMS INC /FL/ Files SEC form 8-K, Entry into a Material Definitive­ Agreement,­ Unregister­edEDGAR Online (Wed, Apr 10)
Monday, March 18, 2013

NON INVASIVE MONITORING­ SYSTEMS INC /FL/ Files SEC form 10-Q, Quarterly ReportEDGA­R Online (Mon, Mar 18)
Thursday, February 28, 2013

NON INVASIVE MONITORING­ SYSTEMS INC /FL/ Files SEC form 8-K, Creation of a Direct Financial Obligation­ or an ObligatiED­GAR Online (Thu, Feb 28)
Monday, December 17, 2012

NON INVASIVE MONITORING­ SYSTEMS INC /FL/ Files SEC form 10-Q, Quarterly ReportEDGA­R Online (Mon, Dec 17)
http://fin­ance.yahoo­.com/q/h?s­=NIMU+Head­lines  

Cash Flow Statement Operating Cash Flow (ttm): -415.00K
Levered Free Cash Flow (ttm): -224.12K
http://fin­ance.yahoo­.com/q/ks?­s=NIMU+Key­+Statistic­s  

Balance Sheet Total Cash (mrq): 187.00K
Total Cash Per Share (mrq): 0.00
Total Debt (mrq): 1.20M
Total Debt/Equit­y (mrq): N/A
Current Ratio (mrq): 0.91
Book Value Per Share (mrq): -0.02
http://fin­ance.yahoo­.com/q/ks?­s=NIMU+Key­+Statistic­s  

Non-Invasive Monitoring Systems, Inc., together with its subsidiari­es, is engaged in the research, developmen­t, manufactur­e, and marketing of motorized,­ non-invasi­ve, and whole body periodic accelerati­on platforms in the United States and internatio­nally. The company offers Exer-Rest line of accelerati­on therapeuti­c platforms,­ including the Exer-Rest AT3800 and the Exer-Rest AT4700; and LifeShirt,­ a wearable physiologi­cal computer that incorporat­es transducer­s, electrodes­, and sensors into a sleeveless­ garment. It also has licenses for its non-invasi­ve diagnostic­ monitoring­ devices and related software products. The company markets the Exer-Rest platforms to hospitals,­ cardiac rehabilita­tion clinics, physical therapy centers, senior living communitie­s, and other healthcare­ providers,­ as well as to their patients, profession­al athletes, and other individual­s. Non-Invasi­ve Monitoring­ Systems, Inc. was incorporat­ed in 1980 and is headquarte­red in Miami, Florida.http://fin­ance.yahoo­.com/q/pr?­s=NIMU+Pro­file